5-Fluorouracil and Weekly Oxaliplatin Combined with Radiotherapy for Locally Advanced Rectal Cancer: Surgical Complications and Long-term Results

Pucciarelli, Salvatore; Urso, Emanuele Damiano Luca; Salvo, Gian Luca De; Aschele, C.; Friso, Maria Luisa; Toppan, Paola; Bruttocao, A; Fabris, G.; Ferraro, B.; Frego, Mauro; Finco, C; Lise, Mario; Nitti, Donato

doi:10.1016/j.arcmed.2006.04.008

Cited by 10 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that preoperative CRT with the XELOX regimen, followed by optimized TME surgery, markedly achieved a higher pCR rate and decreased local recurrence rate of 5–8%, whereas the distant metastatic rate in LARC following TME surgery was 3–6 times higher than the local recurrent rate in previous clinical trials and in the present study ( 25 , 26 ). However, the value of controlling distant metastasis by performing oxaliplatin-based preoperative CRT remains uncertain.…”

Section: Discussioncontrasting

confidence: 49%

Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study

et al. 2017

View full text Add to dashboard Cite

Our previous study reported the favorable short-term outcome and good tolerance of integrating oxaliplatin into capecitabine-based (XELOX regimen) preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). The present study reported the long-term oncological outcome of this phase II study. A total of 47 patients with rectal adenocarcinoma (stage II or III) were enrolled and received radiotherapy (46 Gy in 23 fractions) in combination with capecitabine (1,000 mg/m2, twice daily, on days 1–14 and 22–35) and oxaliplatin (130 mg/m2 on days 1 and 22). Overall survival (OS) rate, disease-free survival (DFS) rate and cumulative incidence of recurrences and long-term complications were calculated or observed. As a result, 41 patients underwent surgery after preoperative CRT, and the cumulative OS rates at 1, 3 and 5 years for these patients were 100.0, 84.5 and 81.8%, respectively. For the 38 patients who received R0 resection, the cumulative OS rates at 1, 3 and 5 years were 100.0, 89.0 and 86.2%, respectively, while the cumulative DFS rates at 1, 3 and 5 years were 94.6, 75.3 and 69.7%, respectively. After follow-up at 84 months, the cumulative incidence rates of local and distant recurrences at 5 years were 6.6 and 28.2%, respectively. Oxaliplatin-associated long-term complications were seldom observed. Overall, the addition of oxaliplatin to capecitabine-based preoperative radiotherapy achieved favorable OS and DFS without increased long-term complications in patients with LARC. Therefore, this preoperative CRT strategy is a feasible option for such patients.

show abstract

Section: Discussioncontrasting

confidence: 49%

Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Oxaliplatin has demonstrated antitumour activity against CRC. 16 However, one of the major obstacles for the application of oxaliplatin is intrinsic and acquired resistance. 16 Oxaliplatin resistance is related to the abnormity in DNA repair and apoptosis.…”

Section: Discussionmentioning

confidence: 99%

“… 16 However, one of the major obstacles for the application of oxaliplatin is intrinsic and acquired resistance. 16 Oxaliplatin resistance is related to the abnormity in DNA repair and apoptosis. 17 SMC1A is known to regulate DNA damage-induced cell-cycle checkpoint and DNA repair.…”

Section: Discussionmentioning

confidence: 99%

Downregulation of SMC1A inhibits growth and increases apoptosis and chemosensitivity of colorectal cancer cells

Feng

Chen

et al. 2015

J Int Med Res

View full text Add to dashboard Cite

ObjectiveThe structural maintenance of chromosomes (SMC) 1A protein is a component of the cohesin multiprotein complex that is essential for sister chromatid cohesion. SMC1A gene mutations have been reported in colorectal cancer. This study aimed to investigate the role of SMC1A gene expression in colorectal cancer in vitro.MethodsSMC1A gene expression was silenced by lentivirus-mediated infection with small interfering RNA (siRNA) in the human colorectal cancer cell line HT-29. Cell proliferation rates, SMC1A mRNA and protein levels, apoptosis and chemosensitivity to oxaliplatin were evaluated using routine in vitro assays, real-time polymerase chain reaction, Western blotting and flow cytometry.ResultsKnockdown of SMC1A protein and mRNA levels resulted in the inhibition of cell proliferation, an increased rate of apoptosis and enhanced chemosensitivity to oxaliplatin in HT-29 cells.ConclusionsThe findings of this study suggest that SMC1A plays an oncogenic role in colorectal cancer and that it might be a promising target for colorectal cancer therapy.

show abstract

“…Nevertheless, the results from several reports show a clear correlation between the pathological T-stage after neoadjuvant therapy and the risk of involved pelvic lymph nodes, with a very low risk (\5%) for patients with pCR [19][20][21].…”

Section: Discussionmentioning

confidence: 99%

Functional outcomes after TEM in patients with complete clinical response after neoadjuvant chemoradiotherapy

et al. 2016

View full text Add to dashboard Cite

show abstract

5-Fluorouracil and Weekly Oxaliplatin Combined with Radiotherapy for Locally Advanced Rectal Cancer: Surgical Complications and Long-term Results

Cited by 10 publications

References 25 publications

Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study

Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study

Downregulation of SMC1A inhibits growth and increases apoptosis and chemosensitivity of colorectal cancer cells

Functional outcomes after TEM in patients with complete clinical response after neoadjuvant chemoradiotherapy

Contact Info

Product

Resources

About